SC262
Asset
Allogeneic hypoimmune CAR T cells target CD22-expressing malignant B cells.
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- CD22
- 2
- Indications
- 1,942
- Trials
- 1
- Developer
Indications
2Large B-cell lymphoma
Phase 1, Active not recruiting, NCT06285422, clinicaltrials.gov, 16 Oct 2026
Non-Hodgkin lymphoma
Phase 1, Active not recruiting, NCT06285422, clinicaltrials.gov, 16 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1,942
- Evidence for its targets2
- Competitors2
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.